Comparative Pharmacology
Head-to-head clinical analysis: AZMACORT versus VANCERIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZMACORT versus VANCERIL.
AZMACORT vs VANCERIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to produce anti-inflammatory and immunosuppressive effects.
Beclomethasone dipropionate is a corticosteroid that exerts anti-inflammatory effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing inflammatory cell migration and cytokine production in the airways.
Two inhalations (200 mcg) three to four times daily or four inhalations (400 mcg) twice daily via oral inhalation.
2 inhalations (84 mcg) 3-4 times daily via oral inhalation.
None Documented
None Documented
Terminal elimination half-life of 3-4 hours for the inhaled route; prolonged in hepatic impairment.
Terminal elimination half-life is approximately 2.8 hours in adults; prolonged in patients with hepatic impairment.
Primarily fecal (60-80%) and renal (10-20%) as metabolites; unchanged drug <5% in urine.
Primarily hepatic metabolism; <10% excreted unchanged in urine, <5% in feces.
Category C
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid